General Information of This Linker
Linker ID
LIN0WQVMZ
Linker Name
Dis linker
Linker Type
Cathepsin-cleavable linker
Antibody-Linker Relation
Cleavable
Formula
C3H6O2S
Isosmiles
O=C(O)CCS
PubChem CID
6514
InChI
InChI=1S/C3H6O2S/c4-3(5)1-2-6/h6H,1-2H2,(H,4,5)
InChIKey
DKIDEFUBRARXTE-UHFFFAOYSA-N
Pharmaceutical Properties
Molecule Weight
106.146
Polar area
37.3
Complexity
44
xlogp Value
0.3909
Heavy Count
6
Rot Bonds
2
Hbond acc
2
Hbond Donor
2
Each Antibody-drug Conjugate Related to This Linker
Full Information of The Activity Data of The ADC(s) Related to This Linker
EDB-L19-diS-DM1 [Investigative]
Revealed Based on the Cell Line Data
Click To Hide/Show 2 Activity Data Related to This Level
Experiment 1 Reporting the Activity Date of This ADC [1]
Efficacy Data Half Maximal inhibitory Concentration (lC50)
237 ng/mL
Negative EDB expression (EDB-)
Method Description
Calculated using four-parameter logistic model #203 with XLfit v4.2 (IDBS)
In Vitro Model Colon cancer HT29 cells CVCL_A8EZ
Experiment 2 Reporting the Activity Date of This ADC [1]
Efficacy Data Half Maximal inhibitory Concentration (lC50)
268 ng/mL
Positive EDB expression (EDB+++/++)
Method Description
Calculated using four-parameter logistic model #203 with XLfit v4.2 (IDBS)
In Vitro Model Normal WI38-VA13 cells CVCL_2759
EDB-diS-L19-4574 [Investigative]
Revealed Based on the Cell Line Data
Click To Hide/Show 2 Activity Data Related to This Level
Experiment 1 Reporting the Activity Date of This ADC [1]
Efficacy Data Half Maximal inhibitory Concentration (lC50)
429 ng/mL
Negative EDB expression (EDB-)
Method Description
Calculated using four-parameter logistic model #203 with XLfit v4.8 (IDBS)
In Vitro Model Colon cancer HT29 cells CVCL_A8EZ
Experiment 2 Reporting the Activity Date of This ADC [1]
Efficacy Data Half Maximal inhibitory Concentration (lC50)
487 ng/mL
Positive EDB expression (EDB+++/++)
Method Description
Calculated using four-parameter logistic model #203 with XLfit v4.7 (IDBS)
In Vitro Model Normal WI38-VA13 cells CVCL_2759
References
Ref 1 Anti-EDB antibodies and antibody-drug conjugates